Gilead Sciences, Inc. (NASDAQ:GILD) Stock Holdings Lifted by Lake Street Advisors Group LLC

Lake Street Advisors Group LLC increased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 18,852 shares of the biopharmaceutical company’s stock after buying an additional 1,078 shares during the period. Lake Street Advisors Group LLC’s holdings in Gilead Sciences were worth $1,741,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. HHM Wealth Advisors LLC grew its holdings in shares of Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 154 shares during the last quarter. Valued Wealth Advisors LLC boosted its position in Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 161 shares during the period. YANKCOM Partnership bought a new position in Gilead Sciences during the 4th quarter worth $28,000. Decker Retirement Planning Inc. acquired a new stake in Gilead Sciences in the fourth quarter worth $29,000. Finally, Crews Bank & Trust bought a new stake in Gilead Sciences in the fourth quarter valued at $31,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Trading Down 1.0 %

NASDAQ:GILD opened at $110.46 on Thursday. The stock has a fifty day simple moving average of $96.56 and a 200 day simple moving average of $89.49. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The firm has a market capitalization of $137.66 billion, a price-to-earnings ratio of 298.54, a price-to-earnings-growth ratio of 0.71 and a beta of 0.18. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $112.11.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be paid a dividend of $0.79 per share. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a yield of 2.86%. The ex-dividend date of this dividend is Friday, March 14th. Gilead Sciences’s payout ratio is 854.05%.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $104.09, for a total transaction of $260,225.00. Following the transaction, the chief financial officer now directly owns 169,061 shares of the company’s stock, valued at approximately $17,597,559.49. The trade was a 1.46 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 542,001 shares of company stock worth $52,230,551 over the last quarter. Corporate insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on GILD. Oppenheimer upped their price target on shares of Gilead Sciences from $105.00 to $115.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 10th. Bank of America restated a “buy” rating and issued a $109.00 price target on shares of Gilead Sciences in a research note on Tuesday, December 10th. Mizuho lifted their price target on Gilead Sciences from $90.00 to $100.00 and gave the company an “outperform” rating in a report on Thursday, November 21st. Morgan Stanley increased their price objective on Gilead Sciences from $113.00 to $123.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. Finally, The Goldman Sachs Group lifted their target price on Gilead Sciences from $85.00 to $96.00 and gave the company a “neutral” rating in a research note on Wednesday, February 12th. Eleven analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $102.08.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.